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Abstract
Multiple Endocrine Neoplasia type 2B (MEN 2B) is an autosomal dominant complex oncologic neurocristopathy
including medullary thyroid carcinoma, pheochromocytoma, gastrointestinal disorders, marphanoid face, and
mucosal multiple ganglioneuromas. Medullary thyroid carcinoma is the major cause of mortality in MEN 2B
syndrome, and it often appears during the first years of life. RET proto-oncogene germline activating mutations are
causative for MEN 2B. The 95% of MEN 2B patients are associated with a point mutation in exon 16 (M918/T). A
second point mutation at codon 883 has been found in 2%-3% of MEN 2B cases. RET proto-oncogene is also
involved in different neoplastic and not neoplastic neurocristopathies. Other RET mutations cause MEN 2A
syndrome, familial medullary thyroid carcinoma, or Hirschsprung’s disease. RET gene expression is also involved in
Neuroblastoma. The main diagnosis standards are the acetylcholinesterase study of rectal mucosa and the
molecular analysis of RET. In our protocol the rectal biopsy is, therefore, the first approach. RET mutation detection
offers the possibility to diagnose MEN 2B predisposition at a pre-clinical stage in familial cases, and to perform an
early total prophylactic thyroidectomy. The surgical treatment of MEN 2B is total thyroidectomy with cervical
limphadenectomy of the central compartment of the neck. When possible, this intervention should be performed
with prophylactic aim before 1 year of age in patients with molecular genetic diagnosis. Recent advances into the
mechanisms of RET proto-oncogene signaling and pathways of RET signal transduction in the development of
MEN 2 and MTC will allow new treatment possibilities.
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Multiple Endocrine Neoplasia Type 2 B (MEN 2B) is a
rare autosomal dominant complex neoplastic neurocris-
topathy characterized by the development of a number
of tumors including medullary thyroid carcinoma
(MTC) and pheochromocytoma (Pheo) with gastroin-
testinal symptoms, marphanoid facies and multiple
ganglioneuromas (GN)/ganglioneurofibromas(GNf) [1].
MTC is present in 100% of MEN 2B cases, and it often
already appears in the 1
st decade of life [2]. MTC is the
main cause of death in MEN 2B patients who don’t
receive early or prophylactic treatment. Surgical treat-
ment of MTC is the only effective therapy in cases with
localized tumor.
Molecular analysis of the RET gene (REarranged during
Transfection) has changed the history of this syndrome, as
it allows the identification of MEN 2B mutations in
asymptomatic patients, and let to perform prophylactic
thyroidectomy in children. RET mutations can also be
responsible for MEN 2A syndrome (MTC, PC and hyper-
parathyroidism) or familial MTC (FMTC). The same RET
gene is causative for Hirschsprung’s disease (HSCR) in a
variable percentage of patients and HSCR can be asso-
ciated with MEN 2 [3-8]. The molecular analysis has given
an important contribution to understand Ret protein func-
tions and the correlation between genotype and phenotype
in RET mutations carriers.
According to genetic diagnosis, RET mutation analysis
can provide early diagnosis and treatment of such a rare
syndrome as MEN 2B, and becomes part of an interna-
tional protocol responding these requirements.
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Although the importance of the neural crest (NC) was
first identified over a century ago, it has gained wide
acceptance in vertebral development over the last 20
years [9]. The neural crest cells contribute to the forma-
tion of structures through-out the body. Therefore, 1
out 3 human congenital malformations involves struc-
tures related to NC.
Diseases arising from NC are particularly diverse in clin-
ical presentation, including endocrinologic, cutaneous,
neurological, digestive, or congenital syndromes [3,9,10].
Following these conditions, in 1974 Bolande suggested
the name neurocristopathies. In his historical publication,
the Author divided neural crest diseases into 2 basic
forms [11,12]. The first includes the simple neurocristo-
pathies, which are characterized by a single pathological
process, generally unifocal and localized. The latter is
represented by neurocristopathy syndromes and complex
neurocristopathies that correspond to multifocal and var-
ied associations of simple neurocristopathies (Table 1).
Taking into account the Boland classification, Albinism,
Hirschsprung’s disease (HSCR), etc.. are considered sim-
ple non neoplastic neurocristopathies. Neuroblastoma
and Medullary Thyroid carcinoma-only (MTC-only) are
simple neoplastic neurocristopathies. Multiple Endocrine
Neoplasia (MEN), Neurofibromatosis, and Familial Neu-
roblastoma associated with HSCR are complex neurocris-
topathies (see Table 1) [10-12].
S i n c eM u l t i p l eE n d o c r i n eN e o p l a s i a( M E N )a r ec o m -
plex neoplastic neurocristopathies, they are syndromes
classified as type 1 and 2, each with specific phenotypic
patterns [13,14]. MEN Type 1 is related to pituitary,
parathyroid and paraneoplastic neuroendocrine tumours.
MEN type 2 occurs in three clinical distinct varieties
with MTC as the common manifestation (see Table 2).
The three varieties are clinically distinct according to
incidence, genetics, age of onset, associations with other
diseases and prognosis [14]:
1) MEN 2A (Sipple’s Syndrome) is characterized by
MTC, pheochromocytoma (Pheo), and primary hyper-
plasia of the parathyroids (HPT).
2) MEN 2B is characterized by MTC, Pheo, mucosal
ganglioneuromatos, and Marfanoid habitus. It is the rar-
est and most aggressive form of MEN type 2.
3) Familial MTC (FMTC) presents a low incidence of
other associated disorders.
HPT is not a feature of MEN 2B. The MEN 2B has
the highest mortality and morbidity. The high mortality
reflects the early onset of MTC (generally during the
first years of life). Unfortunately, at the time of the diag-
nosis an advanced MTC may be present.
Clinical Features of MEN 2B
The clinical features have to be well known, especially in
case of sporadic MEN 2B where they represent the only
possibility to obtain a early suspect of the syndrome.
Gastrointestinal Manifestations
In most of the cases they are the first unspecific manifes-
tations. The patients can present alvus disorders charac-
terized by constipation alternating with diarrhea already
in the first weeks of life. These types of troubles are get-
ting worse. If the MEN 2B patient has a contrast enema
X-ray, his/her colon may show reduced caliber without
haustra; and some diverticula may be present in descend-
ing colon and sigma, other patients show a megacolon.
Intestinal mucosa will progressively develop multiple
pseudo-polyps as result of multiple ganglioneuromas
(GN)/ganglioneurofibromas (GNf) [1]. Intestinal obstruc-
tion resulting from a colonic giant ganglioneuroma is
rare [15,16].
Mucosal Multiple Ganglioneuromas (GN) and
Ganglioneurofibromas (GNf)
Multiple mucosal pseudo-polyps and bumps become
progressively evident in oral cavity, on the mucosal sur-
face of the lips and on the tongue (Figure 1 and 2). They
generally develop during the first months of life [17,18].
Table 1 The Neurocristopathies Classification
Simple neurocristopathies Complex Neurocristopathies
Non Neoplastic-Dysgenetic Neoplastic and Non-Neoplastic
- Hirschsprung’s disease - Neurofibromatosis (Von Recklinghausen disease)
- Albinism - Multiple endocrine neoplasia (MEN) type 1
- Mandibulofacial dysostosis - MEN2A
- Otocephaly - MEN2B
- Congenital Central Hypoventilation - Neurocutaneous melanosis
- Syndrome - Familial neuroblastoma with Hirschprung’ s disease
Neoplastic - CCHS + HSCR = Haddad syndrome
- Neuroblastoma - Waardenburg + HSCR = Shah Waardenburg Syndrome
- Pheochromocytoma
- Medullary thyroid carcinoma (MTC only)
- Noncromaffin paraganglioma
- Carcinoid tumors
Martucciello et al. Italian Journal of Pediatrics 2012, 38:9
http://www.ijponline.net/content/38/1/9
Page 2 of 11Every part of gastrointestinal tract is affected. The clinical
examination of the oral cavity is very important for the
early suspect of the syndrome. In every child with bumpy
lips and tongue associated with intestinal constipation,
MEN 2B should be suspected and excluded.
GN and GNf lesions are characterized by tumors from
mucosal and submucosal layers with enormous hyper-
trophy of nerve fibers (GNf) among ENS. Submucosal
ganglion cells are usually present in normal numbers or
organized in giant ganglia (GN) and always associated
with large trunks of ENS nervous fibers. Ectopic ganglia
inside lamina propia mucosae are present in most of the
cases.
Marfanoid Habitus with Skeletal Deformations and joint
Laxity
Marfanoid body habitus is presents in 65-75% of
patients and it is characterized by an elongated face,
large hand and feet and relatively long extremities
[19-24].
The skeletal abnormalities are characterized by lordo-
sis, kyphosis, kyphoscoliosis, joint laxity, talipes equino-
varus and pectus deformity.
Although skeletal abnormalities may not be pro-
nounced in the first few years, they can be considered
one of the key to early diagnosis for the physician. A tall
stature with disproportionately long limbs and digits, a
long and narrow face with deep-set eyes, and a high, nar-
row palate are often combined with joint hypermobility
and pectus deformities. Chest deformities such as pectus
escavatum or carinatum are related to an overgrowth of
the ribs, pushing the sternum outward or inward. Scolio-
sis is common in MEN 2B and the frequency is higher in
adults. Untreated, significant spinal deformity can lead to
chronic back pain and restrictive lung disease. There is a
correlation between scoliosis and back pain, which occurs
with greater frequency in adults with MEN2B than in the
general population. Joint laxity can be pronounced in
young children and may lead to delayed gross motor
development. Joint dislocation is a rare occurrence. Mild
contractures of elbows, knees, or toes are present in a
small fraction of children and adults. The first toe is
longer than the others and there is a wide space between
the first and second toe (Figure 3). Adults often have an
asthenic body habitus, and crowding of the teeth because
of maxilla and mandible are narrowing.
Inability to Cry Tears
In 2008, Brauckhoff et al reported that 86% of MEN 2B
patients demonstrated inability to cry tears [25].
Palpable Cervical Tumor
Unfortunately, at time of diagnosis most of the sporadic
MEN 2B patients present a palpable thyroid mass or
thyroid nodules, all representing MTCs. As a matter of
fact, MEN 2B is the least common (5-10% of all MEN),
but the most aggressive form of MEN 2. Patients have a
rapid onset of MTCs during the first year of life, and they
h a v eam o r ea g g r e s s i v ef o r mo fc a r c i n o m aw i t hh i g h e r
Table 2 Classification of MEN 2 and occurrence of MTC, and associated disorders (modified by Raue F et al, 2010
Subtype MTC (%) Pheo (%) HPT (%) Associated Diseases
MEN 2A 100 50 25 Cutaneus lichen amyloidosis, hirschsprung’s Disease
MEN 2B 100 50 - Ganglioneuromatosis, marphanoid habitus, megacolon
FMTC 95 - - Rare associated disorders
Figure 1 Characteristic phenotype of MEN 2B including
thickened lips with bumps.
Figure 2 Multiple pseudo-polyps and bumps on the tongue.
The lesions are mucous ganglioneurofibromas and
ganglioneuromas.
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Page 3 of 11morbidity and mortality rates compared with patients
with MEN 2A. Lymph node metastases are reported by
the second year of life [4,26].
Plasmatic Calcitonin and PGT
In all suspected MEN2B patients, plasmatic calcitonin
(CT) in basal condition is measured. Values lower than 14
pg/ml and 19 pg/ml are considered normal in females and
in males respectively [27]. Pentagastrin test (PGT) can be
performed by infusion of a 0, 5 μg/kg of body weight of
pentagastrin contained in 5 mL of 0, 9% NaCl as a bolus.
Plasmatic CT is measured before the infusion of the bolus,
and after 1, 5 and 5 minutes. Stimulated CT values are
considered normal when lower than 30 pg/ml in females
and 110 pg/ml in males [27,28].
PGT is handy used in older children or adult patients.
Nevertheless it is not easy to perform this test in younger
babies, because its normal range is not yet standardized in
the first years of life and because during the first infancy it
could not be completely without risks [4].
For these reasons the test is not very useful for early
diagnosis.
Intestinal Ganglioneuromatosis and Enzymo-histochemical
Pre-operative Diagnosis of MEN 2B
Enzymo-histochemical studies of MEN 2B intestinal
innervation have to be performed by the Acetylcolines-
terase activity (AChE) technique, as described by Kar-
novsky and Roots [29,75,4]. AChE staining is very
useful, because the picture is pathognomonic. The
AChE is evaluated on rectal suction biopsies, as well as
in the histochemical screening of HRSC.
The ganglioneuromas (GN) and the ganglioneurofibro-
mas (GNf) are common conditions affecting peripheral
nerves of MEN 2B intestinal wall. Their presence in the
rectal mucosal and submucous layers is brown stained
and AChE easily shows the enormous hypertrophy of
nerve fibers (GNf) among ENS (Figure 4 and 5). Submu-
cous ganglion cells are usually present in normal num-
bers or organized in giant ganglia (GN) and always
associated with large trunks of ENS nervous fibers. Ecto-
pic ganglia inside lamina propia mucosae are present in
most of the cases. These peculiar AChE findings are so
specific, that the diagnosis of MEN 2B is possible with
the simple use of suction rectal biopsy.
Genetic Analysis of RET Proto-oncogene in MEN type 2
According to literature data it is evident that MEN 2,
unlike other inherited cancer syndromes associated with
inactivation of tumor suppressor gene, results from acti-
vation or “gain-of-function” mutations of RET gene. A
single activating mutation on one allele of the RET
proto-oncogene is sufficient to induce neoplastic trans-
formation [30].
Genetic analysis of the RET proto-oncogene, allows
molecular diagnosis of different neurocristopathies. The
analysis can be performed in MEN 2A and MEN 2B
familial cases, in subjects presenting sporadic MTC, or
affected by HSCR.
Activating mutations of RET seem to be of the order
of 1: 500.000 in the general population [31]. Exons 10,
11, 13, 14, 15 and 16 of the RET proto-oncogene are
analyzed for the detection of point mutations. In MEN
2A/FMTC cases, the analysis is firstly conducted in
exons 10 and 11 by DGGE and subsequently in the
remaining exons, if alterations had not been previously
identified [4,8,32,33].
In 98% of classic MEN 2A families, germline muta-
tions cluster to the extracellular cysteine-rich domain of
the RET gene and involve single base pair substitutions
in one of the five cysteine codons in exon 10 (609, 611,
618, 620) or 11 (634). The great majority of the
Figure 3 The first toe is longer than the others and there is a
wide space between the first and second toe.
Figure 4 Enzymo-histochemical studies of MEN 2B intestinal
innervation performed by acetylcholinesterase on suction
rectal biopsies: giant ganglioneurofibroma. SM = submucous
layer; AChE = acetylcholinesterase.
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C634R (Cysteine to arginine substitution). Rare muta-
tions associated with MEN2A include those in exon 11
(insertion/duplications in codon 635, 637), 13 (codons
768, 790, 791), 14 (codon 804), and 15 (codon 891). The
majority of FMTC kindreds also have germline muta-
tions in the extracellular cysteine-rich region; however,
i nF M T Ct h e ya r em o r ee v e n l yd i s t r i b u t e da m o n g
codon 618, 620 and 634. FMTC is also associated with
non-cysteine mutations in the intracellular tyrosine
kinase domain; this includes exon 13 (codons 768, 790,
791), 14 (codon 804) and 15 (codon 891). Recently it
has been suggested that FMTC is part of MEN 2A spec-
trum, indicating variable allelic penetrance [30].
In MEN 2B patients, exon 16 is primarily screened since
more than 95% of cases present the M918T mutation [34].
A second point mutation at codon 883 has been found in
2%-3% of individual with MEN 2B [35,36]. Tandem RET
mutations of codons 805, 806 and 904 in cis configuration
with the p.V804M mutation have also been reported in
individuals with MEN 2B [37-39].
Finally, all HSCR patients were screened for mutations
in exon 10, since some families presenting the association
of HSCR and FMTC/MEN2A segregate one of the muta-
tions affecting the cysteine residues in exon 10 [34].
DGGE analysis is performed as previously reported
[40]. Sequencing of the altered PCR products is directly
performed using dye terminator chemistry (Dye Termi-
nator Cycle Sequencing Kit - ABI Prism Perkin Elmer,
Norwalk, CT, USA) following the user’s manual instruc-
tions. Electrophoresis of the cycle-sequencing products
is carried out in an ABI 377 Automated Sequencer
(Applied Biosystems, Foster City, CA, USA) and results
are analyzed through an appropriate software.
In MEN 2B and FMTC are generally seen mutations
involving intracellular non-cysteine codons in the tyro-
sine kinase domain. These mutations alter either adeno-
sine triphosphate binding (codons 768, 790, 791, 804 and
891) or the substrate recognition pocket of the catalytic
core (codon 918) resulting in altered substrate specificity
of the RET protein. These altered RET isoforms cause
aberrant phosphorylation of the substrate and activation
of RET signaling pathways that induce cellular transfor-
mation [30].
RET Mutations in Hirschsprung’s Disease
Hirschusprung’s disease is the commonest cause of
intestinal obstruction in the early pediatric age group
w i t har e c o g n i z e dr e c u r r e n c er i s ko f4 %f o rs i b so f
affected individuals in comparison with the general popu-
lation incidence rate of 1/5000 live births with male to
f e m a l er a t i o4 :1 .T h e r ei sar e m a r k a b l ea s s o c i a t i o nw i t h
other genetic diseases, including malformations and/or
chromosomal anomalies that will be discussed succes-
sively in this chapter. Many genetic informations are
obtained from animal models affected with colonic agan-
glionosis showing specific pattern of inheritance and
genetic defects.
Sporadic occurrence accounts for 80-90% of HSCR
cases with a variable expressivity (different length of
aganglionic segments between patients), and an incom-
plete sex dependent penetrance (whether the individual
shows a phenotype of his genotype or not). All these
features of HSCR suggest a more complex pattern of
inheritance (multifactorial) as well as the involvement of
many genes (genetic heterogeneity)
Through segregation analysis on different sets of
patients and their families, different forms of inheritance
were suggested depending on the length of aganglionic
segment. HSCR was classified as autosomal dominant
with incomplete penetrance for long segment HSCR and
autosomal recessive or multifactorial in short segments
HSCR form [41,42].
A first step in understanding the molecular basis of
HSCR was the observation of a little girl who was
affected by total colonic aganglionosis with de-novo
interstitial deletion in chromosome 10 (46xx, del.10
q11.21-q21.2) [43]. Further investigations allowed the
reduction of this region into 200 kb which was the area
of RET proto-oncogene [44]. The molecular strategy
started with the published cDNA sequence at that time
and the exon-intron structure of this gene was recon-
structed by using a PCR based approach [45-47]. The
intronic sequences flanking the 5’ and 3’ ends of each
one of the first 20 exons (which were known at that time)
Figure 5 Enzymo-histochemical studies of MEN 2B intestinal
innervation performed by acetylcholinesterase on suction
rectal biopsies: multiple ganglioneuromas and
ganglioneurofibromas are brown stained. SM = submucous
layer.
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The analysis was later subjected to Single Strand Confor-
mational Polymorphism (SSCP), leding to the identifica-
tion of different forms of mutations [48].
RET gene was found to be mutated in about 35% of
sporadic cases and 49% of familial HSCR cases and in a
higher percent in long HSCR than in short type (76% vs
32%) [17,23]. RET mutations that lead to HSCR can occur
throughout the 21 exons of the gene and at least 89 muta-
tions have been identified, including nonsense mutations,
missense mutations, small deletions, and insertions
[49,50]. On the other hand, mutations leading to MEN2A
or FMTC-familial medullary thyroid carcinoma are point
mutations localized in one of 5 cysteins of the extracellular
domains and they are activating mutations unlike those
causing HSCR [45-47]. HSCR mutations in RET gene lead
to loss of function alleles and they are heterozygous in nat-
ure which suggests haploinsufficiency.
About 5-10% of patients show other mutations in
other genes as Glial cell Lined Derived Neurotrophic
Factor (GDNF), Neurturin (NTN), Endothelin3 (EDN3),
Endothelin B Receptor (EDNRB), Endothelin Converting
Enzyme 1 (ECE1), The Transcriptional factor SOX10,
Smad Interacting protein-1 (SIP1) and PHOX2B gene
[42,50,54-56].
The small percentage of patients with known muta-
tions rises the suspicion about the involvement of other
modifier genes or additional risk factors, some of which
being already mapped [53-55,57].
RET is primarly expressed during embryonic life in
the neural crest, urogenital precursors, adrenal medulla
and thyroid and later on throughout postnatal life in
central and peripheral nervous systems and the endo-
crine system [49].
Mutations in RET gene play an essential role in two
common neurocristopathies: MEN2 (OMIM 171400 and
162300) an autosomal dominant disorder caused by acti-
vating mutations and HSCR(OMIM 142623) which is
believed to be caused by loss of function mutations.
Although HSCR and MEN2 are usually observed in
isolated cases and probably they result from different
molecular and cellular mechanisms due to different
mutation types, the identification of RET mutations
(C618 and C620) in families that have both HSCR and
MEN 2 (FMTC and MEN2A) was surprising. The
underlying mechanism that leads to both diseases is
unknown [58] and it has been reported in a number of
families who have HSCR but carry the mutation leading
to MEN2 [51]. This may give clue about the peculiar
molecular mechanisms of the previous diseases. In order
to explain how the same mutations can produce such
diverse phenotype, we may hypothesize that they are the
results of mutations occurring in different periods of
embryonic and postnatal life.
Another explanation for the complex inheritance pat-
tern of HSCR and the low detection rate for RET muta-
tions is the presence of several common polymorphisms
of RET gene associated with HSCR causing variable risk.
Specific RET haplotypes have been found to act as pro-
tective or predisposing factors or to modulate the sever-
ity of the disease [57,52,59,58,60-62]. A specific
haplotype of a rare allele of Single Nucleotide Poly-
morphism (SNP) of exon 2 (A45A) has been strongly
associated with HSCR while the haplotype of an allele in
exon 14 SNP (S836s) has shown a low penetrant protec-
tive factor against the disease [62]. Another recent study
supports the existence of low penetrant variant of the
RET gene lying within or close to the ACA allele, which
is believed to have an effect on either RET transcription,
splicing or function, and considered a susceptible allele
causing HSCR [63].
Neuroblastoma and RET Proto-oncogene
The role of RET gene in neuroblastoma has been
debated for several years. Indeed, RET is an essential
gene for the development of NC the same tissue from
which neuroblastoma origins. So, the possibility that
RET gene is associated with neuroblastoma carcinogen-
esis has been investigated by several research groups.
However, Hofstra et al and Peaston et al report no RET
gene mutations in both sporadic and hereditary neuro-
blastoma; only one case of RET mutation associated
with NME1 mutation has been reported by Leone et al
[64-66]. It is interesting to note that no RET mutation
has been observed in familial neuroblastoma although
this malignancy onsets frequently in the first year of life
indicating that the carcinogenesis process already starts
during the embryonic life [67].
Experimental evidences indicate that abnormal RET
gene expression may play a role in disturbing the phy-
siological NC development and participate to the neuro-
blastoma cell formation. D’Alessio et al observed that
RET expression induces neuroblastoma cells differentia-
tion and more recently the same researchers demon-
strated that TRKB oncogene, another gene involved in
NC development, cooperate with RET to differentiate
these cells [68,69]. Several neuroblastoma cell lines
express RET together with other tyrosine kinase recep-
tors of the GDNF family (GFR-1, -2 and -3). Bachetti et
al show that several transcription factors deregulate RET
expression in neuroblastoma and Kurotsuchi et al report
that DOK family genes influence the RET gene activity
in this tumor [70,71]. Finally, the role of RET in neuro-
blastoma seems to be strongly associated with the
induction of neuroblastoma cell maturation by retinoic
acid. Retinoic acid is a well known and potent inducer
of terminal cell differentiation of neuroblastoma cells.
Most of all neuroblastoma cell lines are sensitive to the
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employed for the treatment of High-Risk neuroblastoma
patients to induce terminal neuroblastoma cell differen-
tiation after bone marrow depletion [72]. Angrisano
et al have shown that several and complex events such
as modification of DNA methylation are associated with
RET activity by retinoic acid [73]. This observation
should be taken in to account for the treatment of neu-
roblastoma cells by retinoic acid.
Early Diagnosis and Prophylactic Surgery in MEN 2B
Prohylactic total thyroidectomy is performed in gene
mutation carriers in accordance with their potential risk
[84]. Genetic diagnostic screening for MEN 2A should
include at least the cysteine-containing codons 10, 11,
and 16, but also exon 13 and 14. It is now established
that the risk groups are determined by the genotype and
should be used to dictate timing of prophylactic surgery.
Recommendations on the timing of prophylactic thyroi-
dectomy and extent of surgery were presented at the
International Multiple Endocrine Neoplasia Meeting in
2001. The risk was stratified into tree classes using gen-
otype-phenotype correlations [17,18]. Children with
codon 883, 918, and 922 mutations have to be classified
as level 3 (MEN 2B), with the highest risk of early and
aggressive MTC. Total thyroidectomy with central node
dissection is recommended for patients with these muta-
tions by the age of 6 months. Children with RET codon
611, 618, 620, and 634 mutations (MEN 2A) have to be
classified as level 2 or as having a high risk of MTC.
Thyroidectomy with or without central node dissection
is recommended for patients with these mutations
before the age of 5 years. Children with RET codon 609,
768, 790, 791, 804, and 891 mutations have to be classi-
fied as level 1 with the lowest risk of MTC. Operation
in level 1 class is recommended at the age of 10 years
[17].
In agreement with literature data, we believe that cen-
tral compartment cervical lymphadenectomy should be
performed during thyroidectomy for MEN 2B [26].
Homolateral lymph node exploration (2 compartments)
has to be performed in cases with macroscopic evidence
of carcinoma at surgery (Figure 6), and bilateral lympha-
denectomy (3 compartments) in the presence of evident
lymph node metastases. If mediastinal lymph nodes
were metastatic according to CT-scan, limphadenectomy
w o u l db ee x t e n d e dt ot h em e d i a s t i n u m( 4c o m p a r t -
ments) [74].
Immunohistochemical Post-operative Diagnosis in
Resected Thyroids
Resected thyroids have to be weighed, measured, fixed in
formalin and divided in three parts, namely right and left
lobe, and hysthmus. Each part is divided by transverse
serial sections into specimens, and embedded in toto.
Histological sections are obtained from specimens
embedded in paraffin, using the technique of semiserial
sections. The sections obtained have to be stained alter-
natively with hematoxylin-eosin and histochemical reac-
tions for tirocalcitonin (BioGenex, prediluited, policlonal)
chromogranin A (BioGenex, prediluited, clone LK2H10)
and tyroglobulin (BioGenex 1: 10, clone 2H11). For histo-
chemical reactions, routine procedures for the antigen
unmasking are used (treatment in microwave oven in
citrate buffer, ph 6, 10 mM). Dako Envison Peroxidase is
used as revelation system.
Patients underwent to total thyroidectomy show C cell
hyperplasia with “in situ” MTC, or large nodules of
MTC.
Conclusions
Multiple Endocrine Neoplasia type 2B is a complex neo-
plastic neurocristopathy. MEN 2B is the rarest and most
aggressive form of MEN. Prognosis in patients with MEN
2B syndrome depends on early diagnosis and surgical
treatment. According to literature data, MTC occurs in
100% of MEN 2B and is very aggressive [2]. When it
becomes clinically manifest, it can be too late for curative
surgery. Metastases are present at surgery for clinical or
biochemical evidence of MTC in 45% of MEN 2B
patients [26].
In agreement with literature data, in our series of
patients the first clinical signs of MEN 2B affected the
gastroenteric system [32]. These symptoms are associated
with typical marphanoid facies and multiple ganglioneur-
omas. The marphanoid features are not easy to identify
in the first years of life, and ganglioneuromas at that time
may be evident, but can be found if searched carefully.
Gastrointestinal symptoms of MEN 2B generally include
Figure 6 Total thyroidectomy for a MEN 2B patient 3 years old.
Macroscopic evidence of carcinoma in the right lobe. Homolateral
lymphadectomy together with central compartment
lymphadectomy has to be performed during thyroidectomy.
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signs generally appear very early and sometimes are pre-
sent already at birth, but they rarely suggest the diagnosis
of MEN 2B. In children with constipation or stipsis alter-
nating with diarrhoea, the presence of ganglioneuromas
on the tongue and oral mucosa should be investigated, as
well as the typical facies of MEN 2B and the family his-
tory of MTC or PC. In suspected cases, rectal biopsy has
to be performed [29]. In both cases, the pathognomonic
picture of MEN 2B was observed, namely: submucous
plexus hyperplasia with giant ganglia (GN and GNf), sub-
mucous fibromatosis, and ectopic ganglia (Figure 4 and
5) [74]. In our opinion, rectal biopsy should be performed
at first, as it allows diagnosis at an early disease stage.
RET analysis is fundamental to confirm the diagnosis,
and has to be extended to relatives. All carriers of MEN
2B mutations should undergo total thyroidectomy. On
the basis of our experience and of literature data, prophy-
lactic thyroidectomy is justified within the first year of life
in patients with genetic diagnosis of MEN 2B
[76,32,26,77,78].
The presentation of MEN 2B with thyroid mass can
occur in cases with delayed diagnosis. In these patients
the neuromas, the typical facies and the gastrointestinal
symptoms are usually present. In these patients the diag-
nosis must be confirmed as soon as possible, with rectal
biopsy and molecular analysis, in order to perform a total
thyroidectomy associated with limphadenectomy. Fine
needle aspiration of the mass is not advisable, in our opi-
nion, because the result does not change the treatment,
which anyway is based on surgery.
In the pre-operative work up we include cervical sono-
graphy and measurement of biochemical MTC markers:
CT and CEA, useful for the follow up [27]. In case of
thyroid mass, it is advisable to perform CT-scan, abdom-
inal sonography and skeletal scintigraphy, in order to
search for lymph node, hepatic or bone metastases.
Today, PGT has been replaced with molecular genetic
analysis, which is much safer. Actually in pediatric patients
PGT can be ill-tolerated and give false negative results.
When positive, it can indicate the presence of carcinoma
or C cell hyperplasia [79,27]. For these reasons, in our opi-
nion this test is no longer indicated in the diagnosis of
MEN 2B, whereas evaluation of basal plasma calcitonin
CT in MEN 2B patients can play a role in their follow up.
In MEN 2B molecular genetic diagnosis, exon 16 is pri-
marily screened since more than 95% of cases present the
M918T mutation [4,32]. Finally, all HSCR patients were
screened for mutations in exon 10, since some families
presenting the association of HSCR and FMTC/MEN2A
segregate one of the mutations affecting the cysteine resi-
dues in exon 10 [32]. A second point mutation at codon
883 has been found in 2%-3% of individual with MEN 2B
[35,36]. Tandem RET mutations of codons 805, 806 and
904 in cis configuration with the p.V804M mutation have
also been reported in individuals with MEN 2B [37-39].
After the genetic diagnosis of a patient affected with
MEN 2B, every member of his/her family have to be
screened for the M918T mutation. Even in the presence
of family history of MEN 2B, genetic analysis should
always be associated with enzymo-histochemical study
on rectal biopsy, as it allows rapid diagnosis (1 day).
An interesting aspect is the association of MEN 2 with
HSCR. It is well known that RET mutations can be cau-
sative for both HSCR and MEN 2 [80]. In particular, in
MEN 2A patients the most frequent RET mutation
(85%) affects codon 634 of exon 11, while in MEN 2B
patients codon 918 of exon 16 is almost always involved.
In HSCR, RET mutation can affect any portion of the
gene. Interestingly, the most frequent mutations found
in patients with the association of HSCR and MEN 2A/
FMTC involve codons 609, 618 and 620 of exon 10
[82,83,33,45].
In HSCR patients, molecular analysis of standard
MEN 2A/FMTC mutations is therefore recommended
to identify a subpopulation of patients carrying muta-
tions with potential oncologic risk.
The Ret protein is a tyrosine kinase receptor, that plays
an important role in the activation of signalling pathways,
through the phosphorylation of key tyrosine residues, in
response to different ligands. In MEN 2A and MEN 2B,
gain of function RET mutations result in the constitutive
activation of the tyrosine kinase receptor, with subse-
quent phosphorylation and overtrasmission of the signal
by different downstream pathways. The latter can be spe-
cifically activated by the different mutations, which there-
fore result in a large spectrum of possible phenotypes
(MEN 2A, MEN 2B, FMTC, with different degrees of
penetrance and expressivity). On the contrary, RET inac-
tivating mutations are associated with HSCR. Loss of
function mutations result in a reduction of the amount of
functional Ret protein on the cell surface. Mutations
found in patients with HSCR and MEN 2 association are
able to activate the signalling pathways, like in isolated
MEN 2, but the mutated isoform is unable to translocate
to the cell surface. The result of activation in the thyroid
and adrenal glands is tumorigenesis, while the decrease
of functional protein on the cell surface causes HSCR
phenotype [34].
In agreement with literature data, we believe that cen-
tral compartment cervical lymphadenectomy should be
performed during thyroidectomy for MEN 2B [26].
Homolateral lymph node exploration (2 compartments)
has to be performed in cases with macroscopic evidence
of carcinoma at surgery, and bilateral lymphadenectomy
(3 compartments) is necessary in the presence of evident
lymph node metastases. If mediastinal lymph nodes are
metastatic according to CT-scan, limphadenectomy has
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[81].
Despite autotransplantation of parathyroid glands in
the forearm is usually performed, in pediatric patients
we prefer to preserve them in their primary site, in
order to avoid traumas and mechanical insults, that are
frequent in childhood upper limbs [76,26].
MEN 2B patients have to be followed year by year
with measurement of CEA and CT, markers of possible
MTC relapse (more strictly in the first year after sur-
gery). While urinary metanephrines and fractionated
catecholamines (epinephrine, norepinephrine, dopamine)
are useful to identify possible development of PC.
In conclusion, early diagnosis and treatment of
patients with MEN 2B are essential to their survival.
The rarity of this syndrome can cause delayed diagnosis.
MEN 2B is characterized by early clinical signs as non-
specific alvus disorders and, later, development of the
typical facies and presence of ganglioneuromas. These
signs, that precede tumor development, should suggest
the diagnosis, which is based on rectal biopsy and
genetic analysis. The protocol and diagnostic algorithm
of MEN 2B that we propose (see Additional file 1)
seems to offer the best life expectancy to patients
affected by MEN 2B syndrome [84]. Moreover, recent
advances into the mechanisms of RET proto-oncogene
signaling and pathways of RET signal transduction in
the development of MEN 2 and MTC will allow new
treatment possibilities.
Additional material
Additional file 1: Additional file 1. Algorithm for diagnosis and
treatment of MEN 2B. GI = gastrointestinal symptoms.
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